Developer docs
API playgroundTry for free, no card

Search company profiles

Stembio Cell Technologies

Full company profile

uuid000asga

Namestring
Stembio Cell Technologies
Legal namestring
Stembio Cell and Tissue Technologies Inc.
Websiteurl
stembio.com.tr
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Stembio Cell Technologies (Stembio Cell and Tissue Technologies Inc.) is a privately held biotechnology company founded in 2020 and headquartered within the TÜBİTAK Marmara Teknokent (MARTEK) R&D and Innovation zone in Gebze, Kocaeli, Turkey. The company operates as Turkey's first and only hybrid cell and tissue processing center, producing human-derived cellular and tissue products under cGMP and cGTP standards with FDA facility registration, EATCB accreditation, and ISO 9001/14001/45001 certifications. Its infrastructure combines cGMP B and A class sterile production areas within cGMP B/C laboratories, full in-house quality control (sterility, pyrogenicity, flow-cytometry, tumorigenicity), and cryopreservation capacity for 20,000 cellular products, 10,000 cord blood units, and 10,000 tissue products held in liquid nitrogen and -86°C systems.

Stembio monetizes through eight sub-brands organized across three primary revenue mechanics: recurring cord blood and tissue banking subscriptions (STEMCORD), recurring cellular therapy product manufacturing and banking (STEMBIOCELL), one-time human allograft tissue product sales (STEMTISSUE), and regenerative/aesthetic hardware and professional services (EXOSTEM, STEMEST, STEMREGEN, STEMGENE, STEMANIMA). Distribution is hybrid: physician-directed and direct-to-hospital for clinical products (cardiovascular, orthopedic, ophthalmic grafts; cellular therapies), and direct-to-consumer for cord blood banking through website and phone channels. Strategic customers and partners include Yakın Doğu Üniversitesi Hastanesi and Dr. Suat Günsel Girne Üniversitesi Hastanesi in TRNC, LimbuStem for limbal stem cell therapies, and US-based Global Stem Cells Group (partnership signed at ISSCA 2023).

The company is led by Chairman İbrahim Özsu, CEO İlker Halbutoğfulları, and General Medical Director Prof. Dr. Utku Ateş (Histology and Embryology), with Doç. Dr. Durmuş Burgucu as Medical Director. It operates a single-headquarter model serving Turkey and (via partnership) TRNC, with no disclosed funding rounds, parent company, or revenue figures. Quantified value capture to date is framed around Turkey's previously $600M annual tissue/cell import cost, which the company positions itself as reducing via domestic cGMP production.

Short descriptiontext

Stembio Cell Technologies is Turkey's first and only hybrid cGMP-certified cell and tissue processing center, founded in 2020 in Gebze, producing and banking cord blood, cellular therapies, tissue allografts, exosomes, gene therapies, and veterinary stem cell products for hospitals, physicians, and families.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGebze
HQ citystring
Gebze
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapy, cord blood banking, regenerative medicine, tissue allografts, cellular therapy
Industry3 codes
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAA
Stem Cell Therapies (Autologous & Allogeneic)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Cord Blood and Cord Tissue Banking
TypeSubscription Recurring
Description

Storage services for cord blood and cord tissue containing hematopoietic stem cells for family use (autologous) or donation (allogeneic). Services include collection kits, processing, and long-term cryopreservation storage.

stembio.com.tr
2Cellular Therapy Products
TypeSubscription Recurring
Description

Production and banking of cellular therapy products including mesenchymal stem cells (MKH), hematopoietic stem cells (HKH), immunotherapy products, and tissue engineering cellular products under cGMP standards.

stembio.com.tr
3Human Tissue Allograft Products
TypeOne Time License
Description

Processing, storage and distribution of human allograft tissue products including cardiovascular tissues (heart valves, conduits, pericardial patches, vascular patches), musculoskeletal tissues, cornea, amniotic membrane, and skin products.

stembio.com.tr
4Regenerative Medicine Products
TypeHardware Sales
Description

StemRegen products including stromal vascular fraction (Adinizer) and platelet-rich plasma (PRP) for regenerative applications.

stembio.com.tr
5Veterinary Cellular Therapy
TypeProfessional Services
Description

StemAnima provides stem cell therapies for animals including treatments for paralysis, kidney failure, autoimmune diseases, and allergies.

stembio.com.tr
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1EXOSTEM
Description

Mesenchymal Stem Cell Derived Exosome product for skin rejuvenation and cell renewal

stembio.com.tr
+7 more records
Core offering1 text field

Stembio Cell Technologies is a biotechnology center that manufactures and supplies stem cell-based cellular therapy products, human tissue allografts, mesenchymal stem cell-derived exosome products, and regenerative medicine kits, while simultaneously operating a cord blood and cord tissue banking service. Operating under cGMP/cGTP standards at the TÜBİTAK MARTEK R&D zone in Gebze, Turkey, the company serves both individual families (subscription cord blood banking) and healthcare institutions (cellular therapy and tissue products for clinical use), and has expanded into veterinary stem cell therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Turkey's annual $600 million tissue and cell import costs have started to decrease due to StemBio's domestic production capabilities
+2 more records
Product overview1 text field

Stembio Cell Technologies operates as a biotechnology base offering a portfolio of specialized sub-brands focused on stem cell, tissue, and gene technology products and services. The company provides eight distinct product lines: EXOSTEM (mesenchymal stem cell-derived exosomes for skin rejuvenation), STEMBIOCELL (cellular therapy products manufacturing and banking), STEMCORD (cord blood and tissue banking), STEMEST (aesthetic applications and facial rejuvenation), STEMTISSUE (human-derived tissue grafts banking), STEMGENE (gene therapies), STEMREGEN (regenerative medicine applications), and STEMANIMA (veterinary stem cell therapies). The company functions as Turkey's first and only hybrid cell and tissue center, operating under cGMP/cGTP standards, and processes human-derived cells and tissues for clinical use.

Product and service8 records
1EXOSTEM
CategoryRegenerative Medicine
Description

Mesenchymal stem cell-derived exosome product line developed and supplied by Stembio Cell Technologies, intended for use in regenerative medicine applications and targeted at healthcare providers and clinical users.

2STEMBIOCELL
CategoryCellular Therapy
Description

STEMBIOCELL is Stembio's cellular therapy products line, manufacturing and supplying stem cell-based therapeutic products under cGMP/cGTP conditions for clinical use by hospitals, physicians, and healthcare providers.

3STEMCORD
CategoryCord Blood Banking
Description

STEMCORD is Stembio's cord blood and cord tissue banking service, providing collection, processing, cryopreservation at –196 °C, and long-term storage for expectant and new parents (families) under cGMP/cGTP standards.

4STEMEST
CategoryAesthetic Regenerative Medicine
Description

STEMEST is Stembio's aesthetic stem cell applications sub-brand, offering stem cell-based aesthetic products and services for clinical aesthetic providers in Turkey's cosmetic medicine market.

5STEMTISSUE
CategoryTissue Allografts
Description

STEMTISSUE is Stembio's human tissue allograft sub-brand, manufacturing and supplying tissue products processed under cGMP/cGTP conditions for surgical and clinical use by hospitals and physicians.

6STEMGENE
CategoryGene Therapy R&D
Description

STEMGENE is Stembio's gene therapy research and development sub-brand, conducting gene therapy research activities as part of the company's biotechnology portfolio.

7STEMREGEN
CategoryRegenerative Medicine
Description

STEMREGEN is Stembio's regenerative medicine applications sub-brand, supplying regenerative medicine kits such as Adinizer and PRP-based products for clinical use by hospitals, clinics, and aesthetic providers.

8STEMANIMA
CategoryVeterinary Cellular Therapy
Description

STEMANIMA is Stembio's veterinary stem cell therapy sub-brand, providing stem cell-based regenerative therapies for companion animals (e.g., cats and dogs), including treatment of conditions such as feline gingivostomatitis, sold directly to veterinary clinics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Strategic partnership announced at ISSCA World Regenerative Medicine Congress 2023 in Istanbul. Global Stem Cells Group (USA-based, world leader in regenerative medicine) and StemBio signed a collaboration protocol to advance R&D activities in regenerative medicine. Key attendees included Benito Novas (Founder of Global Stem Cells Group), İbrahim Özsu (StemBio Chairman), İlker Halbutoğulları (CEO), and David Christensen (President of Global Stem Cells Group).

2Yakın Doğu Üniversitesi Hastanesi
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint establishment of 'Hücre Doku ve Rejeneratif Uygulamalar ve Araştırma Merkezi' (Cell Tissue and Regenerative Applications and Research Center) - the first and only center of its kind in TRNC. The center provides stem cell therapies in orthopedics, plastic reconstructive surgery, urology, gynecology, and physical medicine.

stembio.com.tr
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership in establishing the Cell Tissue and Regenerative Applications and Research Center in TRNC. Contributed to the first stem cell therapies being administered in Northern Cyprus.

4LimbuStem
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for limbal stem cell production and transplantation. StemBio provides laboratory facilities meeting stem cell and organ transplantation regulations, while LimbuStem (founded by Prof. Dr. Özlem Barut Selver and Dr. Mehmet Gürdal) provides the technology for limbal stem cell culture and transplantation. The partnership enables treatment for patients with limbal stem cell deficiency in Turkey.

stembio.com.tr
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-listed cord blood and tissue banking company operating a similar family-banking subscription model to StemBio's STEMCORD line. Directly comparable on core banking service, regulatory positioning, and consumer go-to-market.

TypeDirect peer
Description

Cord blood and cord tissue banking service now part of Revvity (formerly PerkinElmer). Competes with StemBio's STEMCORD on family banking subscriptions, processing standards, and long-term cryopreservation storage.

TypeDirect peer
Description

One of the largest family cord blood banking services globally, operating under the same subscription-recurring model as StemBio's STEMCORD. Direct overlap on consumer banking and processing technology.

4VetStem Biopharma
TypeDirect peer
Description

US veterinary stem cell therapy provider offering autologous stem cell treatments for companion animals and horses. Directly comparable to StemBio's STEMANIMA veterinary line on indication scope and practice-level distribution.

TypeBroad incumbent
Description

Large non-profit tissue banking and allograft manufacturer with global distribution. Comparable to StemBio's STEMTISSUE allograft portfolio across cardiovascular, musculoskeletal, and skin grafts, though with much broader scale and geography.

TypeRegional player
Description

European family stem cell banking group with operations across multiple EMEA countries. Comparable to StemBio's STEMCORD service and represents the closest regional peer for stem cell banking business model.

7Pluristem Therapeutics
TypeDirect peer
Description

Clinical-stage developer of placenta-derived cellular therapy products. Comparable to StemBio's STEMBIOCELL mesenchymal stem cell product line in underlying technology (allogeneic MSC therapies) and target indications.

TypeBroad incumbent
Description

Commercial-stage cellular medicine company developing MSC-based therapies for inflammatory and immunologic conditions. Overlaps with StemBio's mesenchymal stem cell manufacturing capabilities and clinical applications.

TypeOthers
Description

US-based regenerative medicine company focused on training, products, and clinical services. Listed because it is StemBio's named strategic partner and operates in the same regenerative medicine ecosystem, though the business model (training/advisory) differs.

10RTI Surgical
TypeBroad incumbent
Description

Commercial-stage surgical implant company with a substantial allograft tissue portfolio. Comparable to StemBio's STEMTISSUE cardiovascular and musculoskeletal tissue graft business in product type, regulatory pathway, and hospital-channel distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stembio Cell Technologies

Regenerative Medicinestembio.com.tr

Stembio Cell Technologies is Turkey's first and only hybrid cGMP-certified cell and tissue processing center, founded in 2020 in Gebze, producing and banking cord blood, cellular therapies, tissue allografts, exosomes, gene therapies, and veterinary stem cell products for hospitals, physicians, and families.

What Stembio Cell Technologies does

Stembio Cell Technologies (Stembio Cell and Tissue Technologies Inc.) is a privately held biotechnology company founded in 2020 and headquartered within the TÜBİTAK Marmara Teknokent (MARTEK) R&D and Innovation zone in Gebze, Kocaeli, Turkey. The company operates as Turkey's first and only hybrid cell and tissue processing center, producing human-derived cellular and tissue products under cGMP and cGTP standards with FDA facility registration, EATCB accreditation, and ISO 9001/14001/45001 certifications. Its infrastructure combines cGMP B and A class sterile production areas within cGMP B/C laboratories, full in-house quality control (sterility, pyrogenicity, flow-cytometry, tumorigenicity), and cryopreservation capacity for 20,000 cellular products, 10,000 cord blood units, and 10,000 tissue products held in liquid nitrogen and -86°C systems.

Stembio monetizes through eight sub-brands organized across three primary revenue mechanics: recurring cord blood and tissue banking subscriptions (STEMCORD), recurring cellular therapy product manufacturing and banking (STEMBIOCELL), one-time human allograft tissue product sales (STEMTISSUE), and regenerative/aesthetic hardware and professional services (EXOSTEM, STEMEST, STEMREGEN, STEMGENE, STEMANIMA). Distribution is hybrid: physician-directed and direct-to-hospital for clinical products (cardiovascular, orthopedic, ophthalmic grafts; cellular therapies), and direct-to-consumer for cord blood banking through website and phone channels. Strategic customers and partners include Yakın Doğu Üniversitesi Hastanesi and Dr. Suat Günsel Girne Üniversitesi Hastanesi in TRNC, LimbuStem for limbal stem cell therapies, and US-based Global Stem Cells Group (partnership signed at ISSCA 2023).

The company is led by Chairman İbrahim Özsu, CEO İlker Halbutoğfulları, and General Medical Director Prof. Dr. Utku Ateş (Histology and Embryology), with Doç. Dr. Durmuş Burgucu as Medical Director. It operates a single-headquarter model serving Turkey and (via partnership) TRNC, with no disclosed funding rounds, parent company, or revenue figures. Quantified value capture to date is framed around Turkey's previously $600M annual tissue/cell import cost, which the company positions itself as reducing via domestic cGMP production.

Stembio Cell Technologies firmographics

Firmographics
Name
Stembio Cell Technologies
Legal name
Stembio Cell and Tissue Technologies Inc.
Website
https://stembio.com.tr
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Stembio Cell Technologies is Turkey's first and only hybrid cGMP-certified cell and tissue processing center, founded in 2020 in Gebze, producing and banking cord blood, cellular therapies, tissue allografts, exosomes, gene therapies, and veterinary stem cell products for hospitals, physicians, and families.
Ownership category
akta.pro rank

Stembio Cell Technologies industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAA
Stem Cell Therapies (Autologous & Allogeneic)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Stem cell therapy
  • Cord blood banking
  • Regenerative medicine
  • Tissue allografts
  • Cellular therapy

Where Stembio Cell Technologies is headquartered

Location

Headquarters

HQ city
Gebze

Offices1 record

Markets served

Stembio Cell Technologies business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Cord Blood and Cord Tissue Banking: Storage services for cord blood and cord tissue containing hematopoietic stem cells for family use (autologous) or donation (allogeneic). Services include collection kits, processing, and long-term cryopreservation storage.
  2. Cellular Therapy Products: Production and banking of cellular therapy products including mesenchymal stem cells (MKH), hematopoietic stem cells (HKH), immunotherapy products, and tissue engineering cellular products under cGMP standards.
  3. Human Tissue Allograft Products: Processing, storage and distribution of human allograft tissue products including cardiovascular tissues (heart valves, conduits, pericardial patches, vascular patches), musculoskeletal tissues, cornea, amniotic membrane, and skin products.
  4. Regenerative Medicine Products: StemRegen products including stromal vascular fraction (Adinizer) and platelet-rich plasma (PRP) for regenerative applications.
  5. Veterinary Cellular Therapy: StemAnima provides stem cell therapies for animals including treatments for paralysis, kidney failure, autoimmune diseases, and allergies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Stembio Cell Technologies product offering

Product offering

Core offering

Stembio Cell Technologies is a biotechnology center that manufactures and supplies stem cell-based cellular therapy products, human tissue allografts, mesenchymal stem cell-derived exosome products, and regenerative medicine kits, while simultaneously operating a cord blood and cord tissue banking service. Operating under cGMP/cGTP standards at the TÜBİTAK MARTEK R&D zone in Gebze, Turkey, the company serves both individual families (subscription cord blood banking) and healthcare institutions (cellular therapy and tissue products for clinical use), and has expanded into veterinary stem cell therapies.

Product overview

Stembio Cell Technologies operates as a biotechnology base offering a portfolio of specialized sub-brands focused on stem cell, tissue, and gene technology products and services. The company provides eight distinct product lines: EXOSTEM (mesenchymal stem cell-derived exosomes for skin rejuvenation), STEMBIOCELL (cellular therapy products manufacturing and banking), STEMCORD (cord blood and tissue banking), STEMEST (aesthetic applications and facial rejuvenation), STEMTISSUE (human-derived tissue grafts banking), STEMGENE (gene therapies), STEMREGEN (regenerative medicine applications), and STEMANIMA (veterinary stem cell therapies). The company functions as Turkey's first and only hybrid cell and tissue center, operating under cGMP/cGTP standards, and processes human-derived cells and tissues for clinical use.

Differentiator

Problem solved

Functional benefit

Brands

  • EXOSTEM: Mesenchymal Stem Cell Derived Exosome product for skin rejuvenation and cell renewal
  • STEMBIOCELL
  • STEMCORD
  • STEMEST
  • STEMTISSUE
  • STEMGENE
  • STEMREGEN
  • STEMANIMA

Products and services

  • EXOSTEM Mesenchymal stem cell-derived exosome product line developed and supplied by Stembio Cell Technologies, intended for use in regenerative medicine applications and targeted at healthcare providers and clinical users.
  • STEMBIOCELL STEMBIOCELL is Stembio's cellular therapy products line, manufacturing and supplying stem cell-based therapeutic products under cGMP/cGTP conditions for clinical use by hospitals, physicians, and healthcare providers.
  • STEMCORD STEMCORD is Stembio's cord blood and cord tissue banking service, providing collection, processing, cryopreservation at –196 °C, and long-term storage for expectant and new parents (families) under cGMP/cGTP standards.
  • STEMEST STEMEST is Stembio's aesthetic stem cell applications sub-brand, offering stem cell-based aesthetic products and services for clinical aesthetic providers in Turkey's cosmetic medicine market.
  • STEMTISSUE STEMTISSUE is Stembio's human tissue allograft sub-brand, manufacturing and supplying tissue products processed under cGMP/cGTP conditions for surgical and clinical use by hospitals and physicians.
  • STEMGENE STEMGENE is Stembio's gene therapy research and development sub-brand, conducting gene therapy research activities as part of the company's biotechnology portfolio.
  • STEMREGEN STEMREGEN is Stembio's regenerative medicine applications sub-brand, supplying regenerative medicine kits such as Adinizer and PRP-based products for clinical use by hospitals, clinics, and aesthetic providers.
  • STEMANIMA STEMANIMA is Stembio's veterinary stem cell therapy sub-brand, providing stem cell-based regenerative therapies for companion animals (e.g., cats and dogs), including treatment of conditions such as feline gingivostomatitis, sold directly to veterinary clinics.

Quantifiable outcome

  • Turkey's annual $600 million tissue and cell import costs have started to decrease due to StemBio's domestic production capabilities
  • +2 more outcomes

Companies that use Stembio Cell Technologies

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Stembio Cell Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Stembio Cell Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • Global Stem Cells GroupflagshipStrategic or Co-development Partner · 1 January 2023Strategic partnership announced at ISSCA World Regenerative Medicine Congress 2023 in Istanbul. Global Stem Cells Group (USA-based, world leader in regenerative medicine) and StemBio signed a collaboration protocol to advance R&D activities in regenerative medicine. Key attendees included Benito Novas (Founder of Global Stem Cells Group), İbrahim Özsu (StemBio Chairman), İlker Halbutoğulları (CEO), and David Christensen (President of Global Stem Cells Group).
  • Yakın Doğu Üniversitesi HastanesicoreStrategic or Co-development PartnerJoint establishment of 'Hücre Doku ve Rejeneratif Uygulamalar ve Araştırma Merkezi' (Cell Tissue and Regenerative Applications and Research Center) - the first and only center of its kind in TRNC. The center provides stem cell therapies in orthopedics, plastic reconstructive surgery, urology, gynecology, and physical medicine.
  • Dr. Suat Günsel Girne Üniversitesi HastanesicoreStrategic or Co-development PartnerPartnership in establishing the Cell Tissue and Regenerative Applications and Research Center in TRNC. Contributed to the first stem cell therapies being administered in Northern Cyprus.
  • LimbuStemcoreStrategic or Co-development PartnerCollaboration for limbal stem cell production and transplantation. StemBio provides laboratory facilities meeting stem cell and organ transplantation regulations, while LimbuStem (founded by Prof. Dr. Özlem Barut Selver and Dr. Mehmet Gürdal) provides the technology for limbal stem cell culture and transplantation. The partnership enables treatment for patients with limbal stem cell deficiency in Turkey.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Stembio Cell Technologies competitors and assessment

Company assessment

Direct peers

  • Cryo-Cell International: US-listed cord blood and tissue banking company operating a similar family-banking subscription model to StemBio's STEMCORD line. Directly comparable on core banking service, regulatory positioning, and consumer go-to-market.
  • ViaCord (Revvity): Cord blood and cord tissue banking service now part of Revvity (formerly PerkinElmer). Competes with StemBio's STEMCORD on family banking subscriptions, processing standards, and long-term cryopreservation storage.
  • Cord Blood Registry (CBR) / California Cryobank: One of the largest family cord blood banking services globally, operating under the same subscription-recurring model as StemBio's STEMCORD. Direct overlap on consumer banking and processing technology.
  • VetStem Biopharma: US veterinary stem cell therapy provider offering autologous stem cell treatments for companion animals and horses. Directly comparable to StemBio's STEMANIMA veterinary line on indication scope and practice-level distribution.
  • Pluristem Therapeutics: Clinical-stage developer of placenta-derived cellular therapy products. Comparable to StemBio's STEMBIOCELL mesenchymal stem cell product line in underlying technology (allogeneic MSC therapies) and target indications.

Broad incumbents

  • LifeNet Health: Large non-profit tissue banking and allograft manufacturer with global distribution. Comparable to StemBio's STEMTISSUE allograft portfolio across cardiovascular, musculoskeletal, and skin grafts, though with much broader scale and geography.
  • Mesoblast: Commercial-stage cellular medicine company developing MSC-based therapies for inflammatory and immunologic conditions. Overlaps with StemBio's mesenchymal stem cell manufacturing capabilities and clinical applications.
  • RTI Surgical: Commercial-stage surgical implant company with a substantial allograft tissue portfolio. Comparable to StemBio's STEMTISSUE cardiovascular and musculoskeletal tissue graft business in product type, regulatory pathway, and hospital-channel distribution.

Regional players

  • Cryo-Save (Esperite): European family stem cell banking group with operations across multiple EMEA countries. Comparable to StemBio's STEMCORD service and represents the closest regional peer for stem cell banking business model.

Others

  • Global Stem Cells Group: US-based regenerative medicine company focused on training, products, and clinical services. Listed because it is StemBio's named strategic partner and operates in the same regenerative medicine ecosystem, though the business model (training/advisory) differs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Stembio Cell Technologies social profiles

Digital presence

Stembio Cell Technologies compliance and trust

Trust signal

Compliance5 records

Stembio Cell Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stembio Cell Technologies leadership team

Management profile

Number of profiles

Profiles4 records

Stembio Cell Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stembio Cell Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stembio Cell Technologies

What does Stembio Cell Technologies do?

Stembio Cell Technologies is a biotechnology center that manufactures and supplies stem cell-based cellular therapy products, human tissue allografts, mesenchymal stem cell-derived exosome products, and regenerative medicine kits, while simultaneously operating a cord blood and cord tissue banking service. Operating under cGMP/cGTP standards at the TÜBİTAK MARTEK R&D zone in Gebze, Turkey, the company serves both individual families (subscription cord blood banking) and healthcare institutions (cellular therapy and tissue products for clinical use), and has expanded into veterinary stem cell therapies.

Is Stembio Cell Technologies a public or private company?

Stembio Cell Technologies is a private company. It is classified as unknown and is currently operating.

When was Stembio Cell Technologies founded?

Stembio Cell Technologies was founded in 2020. It employs 51 to 100 people.

Where is Stembio Cell Technologies based?

Stembio Cell Technologies is headquartered in Gebze.

How does Stembio Cell Technologies make money?

Five revenue lines are on record. Cord Blood and Cord Tissue Banking is the primary driver. The others are cellular Therapy Products, human Tissue Allograft Products, regenerative Medicine Products and veterinary Cellular Therapy.

Who are Stembio Cell Technologies's main competitors?

Direct peers on record are Cryo-Cell International, ViaCord (Revvity), Cord Blood Registry (CBR) / California Cryobank, VetStem Biopharma and Pluristem Therapeutics. Broad incumbents are LifeNet Health, Mesoblast and RTI Surgical. Cryo-Save (Esperite) is listed as a regional player. Global Stem Cells Group is listed as an others.

Does Stembio Cell Technologies have an API?

No public API is recorded for Stembio Cell Technologies.

What industry is Stembio Cell Technologies in?

Stembio Cell Technologies's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals